Board Meeting25 May 2026, 10:01 pm
Fredun Pharma Recommends 7% Final Dividend, Bonus Issue 2:1
AI Summary
Fredun Pharmaceuticals Ltd's board approved the standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. They recommended a final dividend of 7% (70 paise per share). The board also approved an increase in authorized share capital from ₹10 Crores to ₹50 Crores and a bonus share issue in the ratio of 2:1, subject to shareholder approval. Additionally, M/s. Nikhil Maniar & Associates and M/s. Joshi Apte & Associates were appointed as Internal Auditor and Cost Auditor, respectively, for FY 2026-27.
Key Highlights
- Final dividend of 7% (70 paise per share) recommended for FY 2025-26.
- Bonus share issue approved in the ratio of 2:1, subject to shareholder approval.
- Authorized share capital increased from ₹10 Crores to ₹50 Crores.
- Standalone and consolidated audited financial results for FY26 approved.
- Internal and Cost Auditors appointed for the financial year 2026-2027.